Akero Therapeutics, Inc.

AKRO

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo	Phase 3	NASH/MASH	-
Efruxifermin	Phase 2	NASH - Nonalcoholic Steatohepatitis	-
EFX	Phase 2	NASH - Nonalcoholic Steatohepatitis	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

April 2026~Efruxifermin

Primary completion for Efruxifermin trial (NCT06161571) in NASH/MASH

⭐Phase 3

April 2026~Placebo

Primary completion for Placebo trial (NCT06161571) in NASH/MASH

Regulatory Approvals

AKRO News